These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
532 related articles for article (PubMed ID: 20384858)
1. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Saha A; Chatterjee SK Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858 [TBL] [Abstract][Full Text] [Related]
2. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474 [TBL] [Abstract][Full Text] [Related]
5. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity. Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590 [TBL] [Abstract][Full Text] [Related]
7. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534 [TBL] [Abstract][Full Text] [Related]
8. Induction of mucosal and systemic immune responses against human carcinoembryonic antigen by an oral vaccine. Huang Y; Fayad R; Smock A; Ullrich AM; Qiao L Cancer Res; 2005 Aug; 65(15):6990-9. PubMed ID: 16061685 [TBL] [Abstract][Full Text] [Related]
9. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201 [TBL] [Abstract][Full Text] [Related]
10. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. Johnson BD; Jing W; Orentas RJ J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167 [TBL] [Abstract][Full Text] [Related]
11. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831 [TBL] [Abstract][Full Text] [Related]
12. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056 [TBL] [Abstract][Full Text] [Related]
14. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483 [TBL] [Abstract][Full Text] [Related]
15. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720 [TBL] [Abstract][Full Text] [Related]
16. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Aarts WM; Schlom J; Hodge JW Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537 [TBL] [Abstract][Full Text] [Related]
17. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322 [TBL] [Abstract][Full Text] [Related]
18. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867 [TBL] [Abstract][Full Text] [Related]